Supriya V Vartak

Employment

• National Institutes of Health Visiting Post-doctoral fellow
  2019 - Present
• Indian Institute of Science Research Associate
  2017 - 2018

Education

Education history is unavailable.

Projects & Funding

Projects & funding information is unavailable.

Publications (9)

• NHEJ inhibitor SCR7 and its different forms: Promising CRISPR tools for genome engineering.
  Gene 2020 DOI: 10.1016/j.gene.2020.144997
  +Save
• G-quadruplex Structures Contribute to Differential Radiosensitivity of the Human Genome.
  iScience 2019 DOI: 10.1016/j.isci.2019.10.033
  +Save
• Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner.
  The FEBS journal 2018 DOI: 10.1111/febs.14661
  +Save
• A Benzothiazole Derivative (5g) Induces DNA Damage And Potent G2/M Arrest In Cancer Cells.
  Scientific reports 2017 DOI: 10.1038/s41598-017-02489-3
  +Save
• Novel BCL2 inhibitor, Disarib induces apoptosis by disruption of BCL2-BAK interaction.
  Biochemical pharmacology 2017 DOI: 10.1016/j.bcp.2017.02.015
  +Save
• A novel inhibitor of BCL2, Disarib abrogates tumor growth while sparing platelets, by activating intrinsic pathway of apoptosis.
  Biochemical pharmacology 2016 DOI: 10.1016/j.bcp.2016.09.028
  +Save
• Identification of a novel BCL2-specific inhibitor that binds predominantly to the BH1 domain.
  The FEBS journal 2016 DOI: 10.1111/febs.13815
  +Save
• Inhibition of nonhomologous end joining to increase the specificity of CRISPR/Cas9 genome editing.
  The FEBS journal 2015 DOI: 10.1111/febs.13416
  +Save
• Enhanced efficacy of pluronic copolymer micelle encapsulated SCR7 against cancer cell proliferation.
  Macromolecular bioscience 2014 DOI: 10.1002/mabi.201400480
  +Save